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Abstract
Obesity is associated with basal-like breast cancer (BBC), an aggressive breast cancer subtype.
The objective of this study was to determine whether obesity promotes BBC onset in adulthood
and to evaluate the role of stromal-epithelial interactions in obesity-associated tumorigenesis. We
hypothesized that hepatocyte growth factor (HGF) plays a promoting role in BBC, which express
the HGF receptor, c-Met. In C3(1)-Tag mice, a murine model of BBC, we demonstrated that
obesity leads to a significant increase in HGF secretion and an associated decrease in tumor
latency. By immunohistochemical analysis, normal mammary gland exhibited obesity-induced
HGF, c-Met and phospho-c-Met, indicating that activation of the cascade was obesity-driven.
HGF secretion was also increased from primary mammary fibroblasts isolated from normal
mammary glands and tumors of obese mice compared to lean. These results demonstrate that
obesity-induced elevation of HGF expression is a stable phenotype, maintained after several
passages, and after removal of dietary stimulation. Conditioned media from primary tumor
fibroblasts from obese mice drove tumor cell proliferation. In co-culture, neutralization of secreted
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HGF blunted tumor cell migration, further linking obesity-mediated HGF-dependent effects to in
vitro measures of tumor aggressiveness. In sum, these results demonstrate that HGF/c-Met plays
an important role in obesity-associated carcinogenesis. Understanding the effects of obesity on
risk and progression is important given that epidemiologic studies imply a portion of BBC could
be eliminated by reducing obesity.
Keywords
Basal-like breast cancer; tumor latency; microenvironment; normal mammary gland; high fat diet-
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INTRODUCTION
Obesity is associated with an increased risk of postmenopausal breast cancer in several
population-based studies, but links between obesity and premenopausal breast cancer have
been controversial [1,2]. The Breast Cancer Prevention Trial suggested an elevated risk of
premenopausal breast cancer among obese women, in contrast to several previous studies
suggesting a protective effect of obesity in this group [3,4]. The Breast Cancer Association
Consortium reported that triple negative tumors are specifically associated with obesity in
younger women [5,6], which is in agreement with several smaller studies that have also
linked obesity or high waist-to-hip ratio with triple negative or basal-like breast cancer
(BBC) [7-9,1]. These studies emphasize that considering tumor subtype is essential when
reporting obesity-related breast cancer risk, and that, taken together, strong associations with
obesity and BBC exist.
BBC is a triple-negative subtype characterized by the lack of expression of estrogen receptor
(ER), progesterone receptor (PR), and type-2 human epidermal growth factor receptor
(HER2) and as such, BBCs are the only breast cancer subtype without a targeted therapy
[10]. BBC disproportionately affects young (< 50 years old) and African-American women
[11,12]. Given that African-Americans experience higher rates of pubertal and adult obesity
[13], and retain more weight after pregnancy [14], it is important to better understand the
biological mechanisms by which obesity, a modifiable risk factor, increases the risk of BBC.
Adding to the complexity of the relationship between obesity and differing breast cancer
subtypes, the effects of obesity on the breast may depend upon the timing of exposure.
Animal studies suggest that early life obesity is a risk factor for breast cancer, showing that
high fat diet-induced obesity alters puberty onset, mammary gland development and
morphology [15,16], as well as decreased tumor latency [17]. However, there has been
limited study on the effects of obesity on mammary carcinogenesis later in life. Of particular
relevance to human cancer, the effect of diet-induced obesity during adulthood has not been
evaluated. Adult obesity is an epidemic in the US and is increasing worldwide [18], hence
understanding the role of obesity exposure during adulthood is a question with high public
health impact.
Stromal-epithelial interactions are known to modulate breast cancer [19]. Stromal
remodeling is important for understanding BBC specifically, because this subtype has
unique interactions with surrounding stroma. Although changes to the stroma are less
dramatic once maturity is reached, recent data has suggested that effects of obesity on
mammary stroma are striking [20-22]. Co-culture of BBC epithelial cells with fibroblasts
upregulates a wide range of cytokines, immune response pathways, and hepatic fibrosis-
associated genes [23]. This is important because stroma-derived hepatocyte growth factor
(HGF) can interact with the c-Met receptor, an important pathway in basal-like
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carcinogenesis examined herein [24,25]. HGF levels are frequently elevated in obese
patients [26] and reduced in patients with weight loss [27]. Elevations of plasma HGF are
correlated with breast cancer, specifically ER-negative [28-30]. We hypothesized that,
similar to results during puberty, obesity would lead to mammary tumorigenesis in
adulthood, potentially through HGF/c-Met-mediated signaling. We selected a preclinical
model focusing on the BBC subtype, since obesity is an important risk factor for triple
negative disease [12,31,11]. Our data demonstrate that in C3(1)-TAg mice associations
between obesity and tumorigenesis mirrored human epidemiologic findings. Furthermore,
our results indicate that HGF may play a role in mediating the onset of obesity-associated




Details are provided in the supplementary materials.
C3(1)-TAg Mouse Model
Animals—C3(1)-TAg mice (described previously [32]) were used to study the role of
obesity on BBC, as these mice were shown to be highly representative of human BBC [33].
Studies were performed with approval and in accordance with guidelines of the Institutional
Animal Care and Use Committee at the University of North Carolina at Chapel Hill (UNC-
CH, NC). Female C3(1)-TAg mice were obtained through a collaboration with the UNC
Lineberger Comprehensive Cancer Center (LCCC) Mouse Phase I Unit (MP1U).
Nulliparous female C3(1)-TAg mice were randomly assigned to various diet groups at
adulthood, 10 weeks of age, after the end of puberty (Model of study design, Supplementary
(Suppl). Figure 1). Diet details are provided in the supplementary materials and (Suppl.
Table 1).
Tumor latency, number, growth and volume—Following initiation of diets at 10
weeks of age, mice were monitored for tumor development by palpating thrice weekly.
Tumor latency was defined as the age at detection of the first tumor. After detection of the
first tumor, tumor volumes were measured weekly over 3 weeks using ultrasound
measurements with the Visualsonics 2000 (Toronto, Canada). Details are provided in the
supplementary material.
Body Weight & Composition—Prior to starting mice on diet and weekly until sacrifice,
body weight was measured. Body composition including lean mass, fat mass, free water
content and total water content of non-anesthetized mice was also measured at 0, 4 and 8
weeks on diet using the EchoMRI-100 quantitative magnetic resonance whole body
composition analyzer (Echo Medical Systems, Houston, TX). Fat mass is presented as
percent fat mass over total body weight. There were no significant declines in absolute lean
mass in grams (data not shown).
Blood Glucose—Blood glucose was measured prior to start of diet and at sacrifice
following a 6h fast using a Bayer Contour Blood Glucose Monitor (Bayer HealthCare LLC,
Tarrytown, NY).
Tissue Harvest—Details are provided in the supplementary materials.
Plasma and Tissue Cytokines Panel—Details are provided in the supplementary
materials.
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Quantitative PCR (qPCR)—Total RNA from normal mammary gland and tumor was
isolated as in Sampey et. al. [34]. Real-time quantitative PCR for HGF, c-Met and
aromatase (Cyp19a1) was performed [34].
Immunohistochemistry/Immunofluorescence of HGF, c-Met, pc-Met, -SMA
and/or SV40-TAg in Normal Mammary Glands and Tumors—Details of
immunohistochemistry (IHC) and immunofluorescence (IF) staining and methods for
scanning slides and analysis are provided in the supplementary materials.
Co-culture studies of stromal-epithelial interactions
Animals—Details are provided in the supplementary materials.
Fibroblast isolation—Normal associated fibroblasts (“NAF”) were isolated from normal
inguinal mammary glands with no evidence of cancer, while cancer associated fibroblasts
(“CAF”) were isolated from tumors from abdominal or inguinal mammary glands with
tumors using methods from Fleming, et. al. [35]. Details are provided in the supplementary
materials.
Co-culture—All culture experiments were completed in triplicate using NAFs and CAFs
from mouse diet groups A, B, and C. 4T1 basal-like breast cancer-like (CRL-2539) cell line
was obtained from ATCC (Manassas, VA). Details of the co-culture studies are provided in
the supplementary materials. The media from these studies was centrifuged at 1620 × g and
supernatant was assayed for HGF concentrations by ELISA (Abcam, Cambridge, MA) using
a Bio-Rad Model 680 Microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA).
Western immunoblot analysis in 4T1 cells treated as described in supplementary materials
for phospho- and total c-Met expression was performed as previously described [36].
Cell Proliferation and Wound Migration Assay
Details of the proliferation study are provided in the supplementary materials. Wound
migration assay was performed as described previously by Camp et al. [23]. Percent wound
closure was calculated by measuring the width of scratch at 0h (time point of scratch) and at
12h (end point of study) using NIH ImageJ 1.46 software and the following formula: (0h
width – 12h width * 100)/0h width.
Statistical Analysis
Data are expressed as mean ± standard error of the mean (SEM). All analysis of variance
(ANOVA) with Tukey’s post-hoc test for statistical differences were performed using SAS
version 9.2 (SAS Institute, Cary, NC) or SPSS (version 20) software (IBM SPSS Statistic
20.0, Armonk, NY). P-values < 0.05 were considered statistically significant.
RESULTS
C3(1)-TAg basal-like tumor latency is decreased by obesity: an association with HGF
Mice were fed control or obesogenic diets in adulthood and tumor and metabolic parameters
were evaluated as indicated in Suppl. Figure 1. Mice made obese by exposure to obesogenic
diets (45% and 60%) exhibited significant decreases in tumor latency compared with lean
controls (10%). The hazard ratios comparing either 45% or 60% to 10% were 2.41 or 2.87,
respectively (Figure 1A). Median times to onset of 10%, 45%, and 60%-fed mice were
19.14, 17.29, and 16.57 weeks, respectively. Obese mice displayed significantly earlier
median latencies (10% vs. 45% p=0.0236 and 10% vs. 60% p=0.0091) but there was no
significant difference between 45% and 60%-fed median latencies (Figure 1A). Using a chi-
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square tests with a degree of freedom of 2, 10% vs. 60% equaled 6.801, 10% vs. 45%
equaled 5.121, and 45% vs. 60% was 0.193. Tumor burden (Figure 1B) or progression
(Figure 1C) were not significantly altered. We next confirmed that expression of the
transgene driving tumorigenesis in C3(1)-TAg mice was not responsible for obesity-
mediated alterations in latency. Indeed, SV40 TAg staining exhibited no significant obesity-
induced elevations in normal mammary gland (Suppl. Figures 2A and B) or tumors (Suppl.
Figures 2C and D). The lack of change in tumor burden in the C3(1)-TAg mice suggested an
effect of obesity on early tumor etiology, rather than on tumor progression.
Obesity strongly regulated HGF/c-Met signaling in normal mammary gland
HGF is a potential mediator of obesity-induced alterations in breast tumor onset since it is
regulated by obesity [26,25,24,2] and could alter tumor etiology. The association between
obesity, HGF, and tumorigenesis has not been investigated to date. Hence we examined
HGF/c-Met signaling in both normal mammary gland and tumors. Obesity significantly
elevated HGF mRNA levels in the normal mammary gland (Figure 1D, P=0.025 10% vs.
60%-fed).
To examine protein expression and localization in tissues, immunohistochemistry (IHC) was
undertaken. HGF expression was primarily localized to stroma with additional staining in
epithelium in normal mammary glands (Figure 2A). Quantification demonstrated that HGF
protein concentrations measured in the stroma were significantly increased in obese 60%-fed
mice compared with 10%-fed lean controls (Figure 2B; P = 0.011). HGF mediates its effects
via its cognate receptor c-Met, a proto-oncogenic tyrosine kinase receptor involved in BBC
[37,25,24]. c-Met mRNA expression did not exhibit significant obesity-induced differences
(Figure 2C). Since c-Met mRNA is degraded rapidly [38], we quantified protein
concentrations through IHC. Representative photomicrographs of cell membrane c-Met
expression in normal mammary gland demonstrated primarily epithelial localization (Figure
2D). Quantification revealed a strong obesity-induced upregulation of c-Met protein
expression (Figure 2E). c-Met protein was significantly increased in obese 45% (P=0.04)
and 60% (P=0.001)-fed mice compared with 10%-fed controls, and between obese 60%
(P=0.025)-fed mice compared with 45%-fed mice. To examine activation of the HGF/c-Met
cascade, phospho-c-Met (pc-Met) expression was quantified. Representative
photomicrographs of normal mammary gland demonstrated both membrane and cytoplasmic
(internalized c-Met [39,40]) staining (Figure 2F). Obesity upregulated expression of pc-Met
(Figure 2G) and significant increases were observed in 45% (P = 0.011) and 60% (P =
0.0001) compared with 10%-fed controls, and between obese 60%-fed (P = 0.0125) mice
and 45%-fed mice. Tumors were next evaluated for obesity-mediated alterations in HGF/c-
Met signaling. In tumors, HGF protein concentrations were not significantly regulated by
obesity (Figure 3A and B). Similarly, neither c-Met mRNA expression nor protein
expression was significantly regulated by diet, although obesity-induced trends existed
(Figure 3C-E). Western immunoblotting of tumors demonstrated variable c-Met protein
expression, with no significant differences detected between groups (Figure 3F). In addition,
no significant differences were observed in the levels of pc-Met in the tumors (Figures 3G
and 3H). Thus, in normal mammary glands obesity positively regulated HGF and c-Met
expression and signaling in obese mice compared to lean. However, significant obesity-
mediated HGF/c-Met regulation in tumors was not evident.
Analysis of metabolic parameters revealed that mice fed 45% and 60% diets were
significantly heavier compared to mice on 10% diet (Figure 4A, P<0.05). Significant
differences in weight could not be detected after week 12 on diet because the sample size
was reduced as mice were sacrificed after tumor formation. Obese mice had greater fat mass
compared to mice fed 10% at 4 weeks on diet (Figure 4B; 45% P=0.009 and 60% P=0.007
versus 10%), and at 8 weeks (45% P=0.0001 and 60% P=0.0002 versus 10%). Leptin is a
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marker of adiposity and increases with fat accretion [41,2]. Mice fed 45% (P=0.005) and
60% (P=0.003) diets exhibited elevated leptin concentrations measured at sacrifice
compared to mice on 10% diet (Figure 4C). Of note, decreased leptin concentrations of
obese mice fed 60% diets compared to 45%-fed mice may be due to disease status of the
mice as these levels were measured at sacrifice after tumor onset, when tumor-induced
cachexia may occur [42-44].
Alterations in tumor onset are likely not due to changes in metabolic parameters since
glucose, insulin or HOMAIR did not vary by obesity (Figures 4D-F). Inflammatory proteins
were measured in plasma, normal mammary, and tumors. Obese mice fed 45% (P=0.023)
and 60% (P=0.048) diets exhibited an increase in plasma TNF-α concentrations compared to
mice on 10% diet (Figure 5A). However, no significant differences were observed in TNF-α
concentrations in the normal mammary gland or tumors. Similarly, plasma and tissue
concentrations of IL-6 and MCP-1 were not significantly modified by obesity (Figures 5B-
C). In addition, plasma concentrations of hormones including estrogen and progesterone
were not altered by obesity (Figures 5 D-E). Finally, aromatase (Cyp19a1) expression was
not detectable by qPCR in any of the diet groups in normal mammary gland or in tumors
(data not shown). Epididymal adipose tissue was used as a positive control: obese adipose
expressed high levels of aromatase compared to lean controls (data not shown).
Obesity and tumor associated fibroblast-derived HGF drove basal-like cell proliferation
and migration
HGF was detected in tissue fibroblasts from normal mammary glands and tumor tissue
(Figure 6A). HGF secretion and function was next investigated in primary fibroblasts.
Secretion of HGF over various time points from 4T1 cells remained low over 24 hours of
mono-culture (Figure 6A). Secretion of HGF from all primary fibroblasts groups at 20 and
24 hours in mono-culture was significantly elevated over earlier time points and 4T1 cells.
Interestingly, fibroblasts isolated from obese mice secreted significantly greater HGF
compared to fibroblasts isolated from lean mice. In addition, within a given diet, CAFs
secreted greater HGF compared to NAFs. HGF secreted from 10%-fed NAFs was
significantly lower than all other groups (P=0.001), and secretion from 60%-fed CAFs was
elevated compared to 10% NAF, 60% NAF, and 10% CAF (P=0.0001, P=0.005, and
P=0.043, respectively). HGF secreted from fibroblasts activated the c-Met signaling cascade
in 4T1 cells similar to recombinant murine HGF (Figure 6C).
Based on an elevation of HGF with obesity in vivo and ex vivo, we assayed cellular
proliferation and migration associated with fibroblast-derived HGF signaling [23]. In
parallel with HGF concentrations from primary NAF and CAFs (Figure 6B), conditioned
media from NAFs and CAFs drove 4T1 proliferation as measured by BrdU incorporation.
The greatest proliferation was driven by fibroblasts isolated from tumors from 60%-fed mice
(Figure 6D, P=0.003 versus 10% NAFs and P=0.02 versus 60% NAFs). The extent of
proliferation was similar to 50ng/ml recombinant HGF-stimulated 4T1 proliferation. Cell
counts revealed identical proliferative capacity (data not shown).
Finally, to test the effect of stromal-epithelial interactions, primary fibroblasts were
cocultured with 4T1 cells and a scratch test “wound assay” was conducted to examine
migratory capacity. In parallel with elevated HGF levels in fibroblast-conditioned media
(Figure 6B) and effects on proliferation (Figure 6D), CAFs demonstrated a significantly
greater effect on wound closure than NAFs in both cases where fibroblasts were isolated
from lean and obese mice (Figure 6E and F). The greatest percent wound closure occurred
when 4T1 cells were co-cultured with 60% CAFs compared to all other groups (60% CAF
vs. 10% NAF: P=0.0001 and 60% NAF: P=0.006). Effects of fibroblasts-epithelial coculture
were significantly reversed in the CAF-4T1 model by an HGF neutralizing antibody (Figure
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6E and F, 10% CAF: P=0.0001 and 60% CAF: P=0.000004 versus untreated). Anti-HGF
antibody treatment demonstrated the greatest inhibition of wound closure in 4T1s co-
cultured with 60% CAFs (P=0.0001 vs. all other groups).
DISCUSSION
Genetic characteristics of BBC have been well-defined, including loss of retinoblastoma
(Rb), p53 mutation, BRCA1 mutation, and signaling defects [10]. However, stromal
interactions likely play a contributing role in BBC etiology, and may underlie higher rates of
local recurrence for this subtype. Fibroblasts are an abundant stromal cell type in the tumor
microenvironment and play a fundamental role in the etiology and progression of tumors
[19,45]. Stromal cell interactions are important in tumor cell proliferation, macrophage
polarization, as well as in reorganization of the extracellular matrix which contributes to
metastasis [46,47,23,48,49,45]. While our previous work using ex vivo co-culture models
suggest unique interactions between human fibroblasts and BBC cells [23,49,50], stromal-
epithelial interactions early in carcinogenesis are poorly understood. Herein we demonstrate
a plausible role of obesity-modulated fibroblast-derived growth factor expression in normal
mammary gland, with implications for etiology of BBC.
Both in vivo and ex vivo, we demonstrated that stroma-derived HGF expression is associated
with obesity in a pre-clinical model of BBC. Normal mammary glands exhibit obesity-
induced increases in HGF and c-Met expression as well as phosphorylated c-Met, providing
an optimal microenvironment for tumorigenesis. Indeed, obesity significantly decreased
tumor latency. Interestingly, decreases in latency occurred in the absence of changes in
either tumor burden or tumor volume. It is possible that the increased HGF and c-Met
expression detected in the normal mammary glands prior to tumor onset act to mediate
tumor etiology in C3(1)-TAg mice. c-Met signaling causes luminal progenitors to
preferentially undergo basal lineage commitment at the expense of luminal cell-fate
specification [25]. There is little work completed on basal-like murine models and to date
only one prior publication from our group has indicated c-Met in basal-like murine tumors
[24]. Evidence presented herein that obesity strongly regulates HGF/c-Met suggests a novel
targetable pathway.
Our data suggest that the effects on BBC etiology include a role for HGF/c-Met and ruled
out metabolic effects as significant mediators of this association. This is important because
obesity has been hypothesized to play a role in carcinogenesis through altered metabolic
homeostasis, including hyperglycemia and hyperinsulinemia secondary to insulin resistance
[51]. Although we observed increased body weight and adiposity in the obese groups
relative to lean controls, obese mice did not develop hyperglycemia, hyperinsulinemia, or
evidence of insulin resistance. Leptin was elevated by obesity in C3(1)-TAg mice. Leptin is
mitogenic, anti-apoptotic, pro-angiogenic, and pro-inflammatory, and, thus, is implicated in
the stimulation, migration, and invasion of tumor cells [52,53,2]. Further studies to
determine the role of leptin in BBC etiology need to be completed. Although significant
increases in systemic TNF- in obese mice were observed, local levels of all cytokines and
chemokines measured indicated that important pro-inflammatory mediators (TNF-α, IL-6
and MCP-1) were not altered by obesity, hence did not contribute to tumor onset in in
C3(1)-TAg mice in this experimental design. However, our previous work and A.J.
Dannenberg’s studies have demonstrated that both obese women and murine models display
elevated macrophage infiltration in normal breast tissue [54,55,22]. Future studies
examining the effects of local inflammation and macrophages on BBC are needed to clarify
the time course of microenvironmental alterations and obesity-mediated tumor onset.
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In epidemiologic studies that have examined obesity risk among all breast cancers or among
cancers stratified by ER status, risk of breast cancer was elevated only among
postmenopausal women [6] leading some to hypothesize that elevated aromatase may play a
role. However, several more recent studies have shown that obesity and adiposity may
increase risk for triple negative breast cancers [4]. In the triple negative subgroup, a
prominent role for aromatase and estrogen signaling is less likely; however we investigated
systemic hormones concentrations and aromatase expression in our model to rule out any
hormonal effects. The lack of obesity-mediated differences in plasma estrogen and
progesterone concentrations, and absence of aromatase expression in the mammary gland or
tumors, suggests that the latency was not driven by systemic or local hormone
concentrations. Furthermore, it has been reported that estrogen levels in C3(1)-TAg mice do
not affect the tumor growth and progression as shown by Yoshidome et. al. [56]. Similarly,
we demonstrated a lack of significant elevations in SV40 TAg levels, indicating that obesity-
mediated alterations in transgene expression could not explain detected reductions in tumor
latency. Therefore, metabolic and hormonal action did not appear to be the primary drivers
of obesity-mediated alterations in latency.
An intriguing finding was the persistent ex vivo release of HGF from fibroblasts. In vivo,
HGF was localized to fibroblasts in both normal mammary glands and tumor tissues. HGF
secretion was significantly increased from NAFs from obese mice compared to lean,
demonstrating that in vivo obesity-induced elevation of HGF expression is a phenotype that
is conserved in primary culture. In addition, CAFs derived from mice on either diet secreted
significantly greater HGF than NAFs, demonstrating that the tumor microenvironment
primes for elevated HGF release from fibroblasts. Conditioned media from fibroblasts
induced cell proliferation in direct correlation with HGF concentrations secreted from the
NAFs and CAFs, with obese-derived tumor fibroblast conditioned media being as effective
as recombinant HGF in driving epithelial cell proliferation. Obesity regulation of HGF/c-
Met driven proliferation is one mechanism demonstrated in vitro that may be an underlying
mechanism in vivo.
To probe the HGF/c-Met mechanism in a faithful model of the mammary
microenvironment, we cocultured primary fibroblasts from C3(1)-TAg diet-exposed animals
with 4T1 BBC-like epithelial cancer cells [23,46,54] and completed a scratch test wound
response assay. Earlier work by our group demonstrated a strong wound response signature
in more aggressive and basal-like breast cancer samples from patients, as well as in the
normal mammary gland extra-tumoral microenvironment [45,48,47,50.]. In fibroblasts/4T1
co-culture herein, completeness of wound closure was elevated in association with HGF
expression increases, such that fibroblasts isolated from obese mice and/or from tumors
demonstrated the greatest extent of wound closure. Since HGF is the only known ligand of
c-Met, inhibiting HGF signaling using a neutralizing antibody is effective at blunting c-Met
activation [57,49,50]. Our results demonstrated that neutralization of HGF had the most
dramatic effects in conditions where fibroblast-driven proliferation was the greatest,
demonstrating specificity for HGF/c-Met signaling. The persistence of HGF secretion from
primary fibroblasts ex vivo is consistent with work demonstrating that HGF is secreted in
greater amounts from primary adipocytes isolated from obese versus lean subjects [27]. Our
work presented here suggest that fibroblast-derived HGF may be regulated by obesity
through epigenetic means [58], which could have long-lasting effects on the mammary gland
stroma.
CONCLUSIONS
In sum, our data demonstrate that obesity reduces BBC latency in C3(1)-TAg mice. HGF
may be a potential mediator of tumor onset: expression is elevated by obesity in normal
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mammary glands and persists in isolated primary fibroblasts. Indeed, in vitro modeling of
the normal and tumor microenvironment demonstrate that fibroblasts derived from tumors
were an important regulator of proliferation and wound response, specifically through HGF/
c-Met signaling. Increased proliferation and motility induced by HGF allows for cells with
already elevated proliferative rates (such as the TAg-overexpressing epithelium of this
model) to locally invade and develop tumors. c-Met inhibitors are currently in clinical trials
for basal-like breast cancer [59]. Our findings support a novel role for obesity-mediated
HGF/c-Met signaling as modifiable risk factor for basal-like tumor onset, which has
important public health implications with regard to BBC risk. Whether increased risk of
breast cancer associated with obesity is reversible with weight loss is still an important area
of uncertainty.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Obesity-mediated decrease in latency correlates with elevated HGF expression
A) Upon initiation of 10, 45 and 60% kcal derived from fat diets at 10 weeks of age, mice
were palpated three times weekly for tumor onset. Hazard ratios comparing either 45% or
60% to 10% were 2.41 or 2.87, respectively. Median latencies are indicated ((10% vs. 45%
p=0.0236 and 10% vs. 60% p=0.0091). B) Number of tumors was detected at sacrifice
(n=15 mice). C) Tumor volume was measured by ultrasound (n=15 mice). D) HGF mRNA
expression was determined using qPCR analysis in n=8 normal mammary glands. * 10% vs.
60% (P = 0.025).
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Figure 2. Obesity upregulated HGF, c-Met, and pc-Met expression in normal mammary glands
A) Representative photomicrographs (40X) of HGF staining in negative control (secondary
only), 10%, 45% and 60% diet groups in normal (unaffected) mammary glands. Arrows
indicate positive HGF staining in the stroma. B) Total HGF protein levels of the normal
mammary glands were quantified using the Aperio ImageScope color deconvolution
algorithm for n = 2 sections from 5 mice per diet group. * 10% vs. 60% (P = 0.011). C) c-
Met mRNA expression was determined using qPCR analysis in normal mammary glands for
n = 7. D) Representative photomicrographs (40X) of the IHC analysis of negative control
and membrane localized c-Met staining in 10%, 45%, and 60% diet groups (arrows). E)
Total c-Met protein levels in normal mammary glands were measured using the Aperio
ImageScope membrane algorithm and quantified as above. * 10% vs. 45% (P = 0.04) and
10% vs. 60% (P = 0.001); ^ 45% vs. 60% (P = 0.025). F) Representative photomicrographs
(40X) of the IHC analysis of negative control and pc-Met staining in 10%, 45%, and 60%
diet groups. G) Total pc-Met protein levels in normal mammary glands were measured using
the Aperio ImageScope color deconvolution algorithm and quantified as above. * 10% vs.
45% (P = 0.011) and 10% vs. 60% (P = 0.0001); ^ 45% vs. 60% (P = 0.0125).
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Figure 3. Obesity minimally modified HGF, c-Met, and pc-Met expression in tumors
A) Representative photomicrographs (40X) of the IHC analysis of tumors showing HGF
staining in negative control and 10%, 45%, and 60% diet groups. B) HGF protein levels in
tumors were quantified using the Aperio ImageScope color deconvolution algorithm for n =
2 sections from 5 mice per diet group. C) c-Met mRNA expression was determined using
qPCR analysis in tumor tissues for n = 7. D) Representative photomicrographs (40X) of the
IHC tumor analysis of membrane localized c-Met staining in negative controls and 10%,
45%, and 60% diet groups (arrows). E) Total c-Met protein levels in tumors were measured
using the Aperio ImageScope membrane algorithm and quantified as above. F) Western
immunoblot expression of c-Met in n=3 tumors per diet group and quantification (c-Met
normalized to amido black staining loading control). G) Representative photomicrographs
(40X) of the IHC tumor analysis of pc-Met staining in negative controls and 10%, 45%, and
60% diet groups. H) Total pc-Met protein levels in tumors were measured using the Aperio
ImageScope color deconvolution algorithm and quantified as above.
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Figure 4. Diet affects body weight, body composition, and plasma leptin concentration but not
metabolic parameters
A) Body weight increased in proportion with fat content in diet. * 10% vs. 45% (P <0.05)
over weeks 3 - 12 (solid line) and ^ 10% vs. 60% (P < 0.05) over weeks 2 - 12 (dashed line).
N= 15 mice per group at start of diet. B) Percent fat content relative to total body mass is
shown for n = 15. At 4 weeks on diet * 10% vs. 45% (P=0.009) and 10% vs. 60% (P=0.007)
and at 8 weeks on diets ^ 10% vs. 45% (P=0.0001) and 10% vs. 60% (P=0.0002). C) Leptin
levels in plasma at sacrifice were measured (n = 12). * 10% vs. 45% (P=0.005) and 10% vs.
60% (P=0.003). D) Blood glucose concentrations prior to start of diet and at sacrifice were
measured in 6 hour fasted mice (n = 15 mice). E) Insulin in plasma at sacrifice was
measured (n = 12). F) Homeostasis model assessment of insulin resistance (HOMAIR) at
sacrifice (n = 12).
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Figure 5. Plasma levels of TNF-α, but not IL-6 or MCP-1, nor tissue levels of cytokines are
regulated by obesity
Cytokine and chemokine levels of A) TNF-α, B) IL-6 and C) MCP-1 in plasma, normal
mammary gland, and tumor tissues; or levels of hormones D) estrogen and E) progesterone
were measured at sacrifice (n=12 for plasma samples, n=4 for normal mammary glands and
n=5 for tumors). * TNF-α plasma levels: 10% vs. 45% (P = 0.023 and 10% vs. 60% (P =
0.048).
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Figure 6. HGF mediates wound closure driven by obese and/or cancer-derived fibroblasts
A) Representative confocal photomicrographs (63X) of HGF (green) co-stained with
fibroblast marker - smooth muscle actin (SMA, red) in normal mammary and tumor.
Nucleus (blue) is stained with DAPI. B) HGF was quantified in conditioned media at
indicated time points from mono-cultures of 4T1 basal like epithelial cells, as well as
primary normal associated fibroblasts (NAF) and cancer associated fibroblasts (CAF)
isolated from lean (10%-fed mice) and obese (60%-fed mice) for n=3 experiments. *P =
0.0001 vs. all other groups; + vs. all other groups (P=0.001); # vs. 10% NAF (P=0.0001),
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60% NAF (P=0.005), and 10% CAF (P=0.043). C) phospho-c-Met and total c-Met
expression in 4T1 cells was determined using Western immunoblot analysis after 15 min
treatment with conditioned media (CM) from primary 60% CAFs or recombinant mouse
HGF (50 ng/ml). Loading control is non-specific band from c-Met immunoblot. D)
Proliferation index measured using BrdU incorporation is shown for n = 3 experimental
groups. * vs. HGF (50 ng/ml) (P = 0.024); # vs. 60%-CAF with 10%-NAF (P = 0.003) and
60% NAF (P = 0.02). E) Fluorescently labeled 4T1 cells were co-cultured with NAFs or
CAFs isolated from lean (10% diet) and obese (60% diet) mice, with or without HGF
neutralizing antibody during the 24 hour co-culture period and the 12 hour scratch test.
Representative photomicrographs of wound migration assay at 0h (time point of scratch) and
12h (end of study). F) Percent wound closure is shown for n = 3 experiments. * vs. control
(no anti-HGF) for 10% CAF (P=0.0001) and 60% CAF (P=0.0004). + vs. 10% NAF
(P=0.0002) and vs. 60%-NAF (P=0.006) controls. # vs. all groups (P = 0.0001).
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